A new research review published in Cannabis and Cannabinoid Research support the notion that cannabidiol (CBD) is safe for human consumption. Investigators Iffland Kerstin and Grotenhermen Franjo from German research center nova-insisut built upon Mateus Machado Bergamaschi's comprehensive survey that analyzed various studies involving controlled CBD for humans and animals. This new review updated the existing information with new findings from both preclinical and clinical trials. Researchers concluded that the studies indicated CBD had no adverse psychological effect on blood pressure, heart rate, body temperature, glucose levels, pH, pressure exerted by carbon dioxide or oxygen, hematocrit, gastrointestinal transit, emesis, rectal pressure, or potassium and sodium levels. One study found 60 mg/kg of CBD given to mice three days weekly for twelve weeks had no adverse effects on any of their bodily movements. Chronic use of CBD in humans has proven to have no neurological, psychiatric, or clinical adverse effects, nor any respiratory depression or cardiovascular complications.
The new review also indicates CBD may possess immunomodulatory and neuroprotective properties, and may have the ability to support the treatment of heroin addiction, reduce seizures, manage psychosis, inhibit cancer, and reduce anxiety. There may be some drug interaction between CBD and pharmaceutical medications, including any medications metabolized by enzymes from the cytochrome P450 family, which include: Lipitor (atorvastatin), Xanax (alprazolam), caffeine, naproxen, ibuprofen, acetaminophen, and codeine. CBD may also inhibit the enzymes CYP2D6 and CYP2C9, which could reduce how medications like omeprazole, risperidone, warfarin, and diclofenac are metabolized. Additionally, in vitro studies have noted CBD inhibits the ABC transporters P glycoprotein and Breast Cancer Resistance Protein, which could interfere with some anticancer drugs binding to transporters. On the other hand, certain drug interactions have been beneficial, and one 8-week-long clinical study on children with epilepsy found CBD increased the bioavailability of the anti-epileptic medication clobazam, so patients could more effectively manage their seizures while reducing their dose of the anti-epileptic medication.
This information has been provided by Medical Marijuana Inc. and approved by our Chief Medical Officer.